scholarly journals NEAT1 isoform expression in breast cancer

2020 ◽  
Vol 4 ◽  
pp. 4-4
Author(s):  
Stacey L. Edwards ◽  
Juliet D. French
2015 ◽  
Vol 24 (25) ◽  
pp. 7421-7431 ◽  
Author(s):  
Jennifer L. Caswell ◽  
Roman Camarda ◽  
Alicia Y. Zhou ◽  
Scott Huntsman ◽  
Donglei Hu ◽  
...  

2002 ◽  
Vol 87 (12) ◽  
pp. 1411-1416 ◽  
Author(s):  
L C Murphy ◽  
E Leygue ◽  
Y Niu ◽  
L Snell ◽  
S-M Ho ◽  
...  

PLoS Genetics ◽  
2017 ◽  
Vol 13 (3) ◽  
pp. e1006589 ◽  
Author(s):  
Thomas P. Stricker ◽  
Christopher D. Brown ◽  
Chaitanya Bandlamudi ◽  
Megan McNerney ◽  
Ralf Kittler ◽  
...  

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Franziska M. Wuerfel ◽  
Hanna Huebner ◽  
Lothar Häberle ◽  
Paul Gass ◽  
Alexander Hein ◽  
...  

Abstract The immunosuppressive human leukocyte antigens HLA-G and HLA-F are expressed on trophoblast and malignant cells. Four membrane-bound and three soluble HLA-G protein isoforms have been described, which have different immunosuppressive potentials. HLA-F has three transcript variants, resulting in three different protein isoforms. The aim of this study was to evaluate the prognostic and predictive value of HLA-G and HLA-F protein isoform expression patterns in patients with breast cancer. Core biopsies were taken at diagnosis in patients with HER2+ (n = 28), luminal B-like (n = 49) and triple-negative (n = 38) breast cancers who received neoadjuvant chemotherapy. Expression levels of HLA-F and -G were correlated with the pathological complete response (pCR). Protein expression was determined by Western blot analysis, using two antibodies for each HLA, specific for different isoforms. The protein expression of HLA isoforms did not significantly differ between breast cancer subtypes. However, some initial indications were found for an association between the soluble HLA-G6 protein isoform and pCR in HER2+ breast cancer. The study provides preliminary evidence for the evaluation of HLA-G isoform expression, in particular HLA-G6, as a possible new marker for pCR in HER2+ breast cancer.


BMC Cancer ◽  
2013 ◽  
Vol 13 (1) ◽  
Author(s):  
Anna Machleidt ◽  
Stefan Buchholz ◽  
Simone Diermeier-Daucher ◽  
Florian Zeman ◽  
Olaf Ortmann ◽  
...  

2021 ◽  
Vol 9 (1) ◽  
Author(s):  
Arpankumar Choksi ◽  
Apoorva Parulekar ◽  
Richa Pant ◽  
Vibhuti Kumar Shah ◽  
Ramakrishna Nimma ◽  
...  

Abstract Background Highly proliferating cancer cells exhibit the Warburg effect by regulation of PKM alternative splicing and promoting the expression of PKM2. Majority of the alternative splicing events are known to occur in the nuclear matrix where various MARBPs actively participate in the alternative splicing events. SMAR1, being a MARBP and an important tumor suppressor, is known to regulate the splicing of various cancer-associated genes. This study focuses on the regulation of PKM alternative splicing and inhibition of the Warburg effect by SMAR1. Methods Immunohistochemistry was performed in breast cancer patient samples to establish the correlation between SMAR1 and PKM isoform expression. Further, expression of PKM isoforms upon modulation in SMAR1 expression in breast cancer cell lines was quantified by qRT-PCR and western blot. The acetylation status of PTBP1 was estimated by immunoprecipitation along with its enrichment on PKM pre-mRNA by CLIP in SMAR1 knockdown conditions. The role of SMAR1 in tumor metabolism and tumorigenesis was explored by in vitro enzymatic assays and functional assays upon SMAR1 knockdown. Besides, in vivo tumor formation by injecting adeno-SMAR1-transduced MDA-MB-231 cells in NOD/SCID mice was performed. Results The expression profile of SMAR1 and PKM isoforms in breast cancer patients revealed that SMAR1 has an inverse correlation with PKM2 and a positive correlation with PKM1. Further quantitative PKM isoform expression upon modulation in SMAR1 expression also reflects that SMAR1 promotes the expression of PKM1 over tumorigenic isoform PKM2. SMAR1 deacetylates PTBP1 via recruitment of HDAC6 resulting in reduced enrichment of PTBP1 on PKM pre-mRNA. SMAR1 inhibits the Warburg effect, tumorigenic potential of cancer cells, and in vivo tumor generation in a PKM2-dependent manner. Conclusions SMAR1 regulates PKM alternative splicing by causing HDAC6-dependent deacetylation of PTBP1, resulting in reduced enrichment of PTBP1 on PKM pre-mRNA. Additionally, SMAR1 suppresses glucose utilization and lactate production via repression of PKM2 expression. This suggests that tumor suppressor SMAR1 inhibits tumor cell metabolism and tumorigenic properties of cancer cells via regulation of PKM alternative splicing.


PLoS ONE ◽  
2021 ◽  
Vol 16 (5) ◽  
pp. e0251515
Author(s):  
Joshua K. Stone ◽  
Lana Vukadin ◽  
Eun-Young Erin Ahn

Emerging evidence has shown that active enhancers are abundantly transcribed, generating long non-coding RNAs, called enhancer RNAs (eRNAs). While putative eRNAs are often observed from RNA sequencing, the roles of most eRNAs remain largely unknown. Previously, we identified putative enhancer regions at the MALAT1 locus that form chromatin-chromatin interactions under hypoxia, and one of these enhancers is located about 30 kb downstream of the NEAT1 gene and -20 kb upstream of the MALAT1 gene (MALAT1–20 kb enhancer). Here, we report that a novel eRNA, named eRNA of the NEAT1-MALAT1-Locus (eNEMAL), is transcribed from the MALAT1–20 kb enhancer and conserved in primates. We found that eNEMAL is upregulated in response to hypoxia in multiple breast cancer cell lines, but not in non-tumorigenic MCF10A cells. Overexpression and knockdown of eNEMAL revealed that alteration of eNEMAL level does not affect MALAT1 expression. Instead, we found that eNEMAL upregulates the long isoform of NEAT1 (NEAT1_2) without increasing the total NEAT1 transcript level in MCF7 breast cancer cells, suggesting that eNEMAL has a repressive effect on the 3’-end polyadenylation process required for generating the short isoform of NEAT1 (NEAT1_1). Altogether, we demonstrated that an eRNA transcribed from a MALAT1 enhancer regulates NEAT1 isoform expression, implicating the MALAT1–20 kb enhancer and its transcript eNEMAL in co-regulation of MALAT1 and NEAT1 in response to hypoxia in breast cancer cells.


2011 ◽  
Vol 13 (4) ◽  
Author(s):  
Diana Connolly ◽  
Zhixia Yang ◽  
Maria Castaldi ◽  
Nichelle Simmons ◽  
Maja H Oktay ◽  
...  

2006 ◽  
Vol 8 (S2) ◽  
Author(s):  
RA Alcock ◽  
JH Pringle ◽  
JA Shaw ◽  
DL Holliday ◽  
M Allen ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document